



# CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS



**2025**  
Annual Report



About the CDMRP .....2  
 FY24 and FY25  
 Research Programs.....3  
 Partnerships ..... 4  
 Managing, Monitoring and  
 Evaluating Research Investments .... 5  
 Impact Highlights..... 6  
 FY24 Programs and Investments ..... 8  
 Appendix A:  
 FY24 PRCRP and PRMRP  
 Topic Area Investment Summary ... 16

**Annual Report  
 September 30, 2025**

Department of War  
 Defense Health Agency Research and  
 Development - Medical Research  
 and Development Command  
 Congressionally Directed Medical  
 Research Programs

ATTN: FCMR-CD  
 1077 Patchel Street,  
 Fort Detrick, Maryland 21702-5024  
 Phone: 301-619-7071  
 Fax: 301-619-7796  
<https://cdmrp.health.mil>

**Letter from the Director**

*Dear Consumer Advocates, Researchers, Military Members,  
 Veterans and Families,*

It is my privilege to present the 2025 Annual Report on behalf of the Congressionally Directed Medical Research Programs (CDMRP). The work we do is more than science: it's service. Our two-tier review process identifies research that supports the Warfighter, advances medical readiness, fosters groundbreaking research, and, most importantly, gives hope to those affected by disease, injury and trauma.

This year brought unprecedented changes, including a 57% reduction in fiscal appropriations, from \$1.509 billion in FY24 to \$650 million in FY25. Yet, our response to these changes affirms the resilience, adaptability and united sense of purpose that define this organization. Our team of dedicated professionals executed 100% of FY24 funds and swiftly initiated FY25 activities, adapting investment strategies and releasing funding opportunities in line with congressional direction and the needs of the patient communities. We remain committed to maintaining low management costs to ensure maximum investment in high-impact, innovative research that improves the lives of Service Members and their Families, Veterans and civilians alike.

Through collaborative partnerships with the National Institutes of Health, the Department of Veterans Affairs, and many others, we are redefining what's possible in military and civilian medicine.


I encourage you to read this report to learn more about our successes, key advancements and partnerships over the past year, and to visit our website for more detailed program information and an overview of our two-tier review funding process.

On behalf of the entire CDMRP team, we are honored by the support from Congress and consumer advocates, scientists, clinicians, academia and military communities. Together, we are not just enduring change, we are leading through it.

**U.S. Army Colonel Mark Hartell, Ph.D.**  
*Director, CDMRP*

**VISION:** Transform health care through innovative and impactful research

**MISSION:** Responsibly manage collaborative research that discovers, develops and delivers health care solutions for Service Members, Veterans, their Families and the American public






# ABOUT THE CDMRP

The CDMRP is a funding organization within the Defense Health Agency that oversees the investment of congressionally directed appropriations to support groundbreaking, high-impact, meritorious research projects targeting critical research gaps. The CDMRP originated in 1992 when the U.S. Congress first appropriated funds to the then Department of Defense specifically for breast cancer research. Since then, Congress appropriated funding for additional targeted research programs.

The Department of War does not request funding for the CDMRP as part of the president's annual budget submission. In response to input from community members, including consumer advocates, survivors and people living with a disease or injury experience, Congress adds funding for the CDMRP into the annual defense appropriations bill. Congressional appropriations are annual and not guaranteed each year. Award agreements include full obligation of funding, ensuring availability of requested funds to support the entire research project, provided the funded study meets the award's terms and conditions.

The CDMRP releases publicly competed funding opportunities designed to target research specific to the congressionally directed disease, injury or condition. While individual programs are unique in their focus, all programs managed by the CDMRP share the common goal of aiming to advance paradigm-shifting research leading to improvements in patient care or breakthrough technologies and resources for clinical benefit. The CDMRP uses a flexible management process to maintain the individuality of each program while considering congressional intent and the needs of the Department of War, the research and advocacy communities and the public at large. The graphic below depicts each step in the CDMRP management process, beginning with receipt of congressional appropriations and ending with completion of the funded research.

The CDMRP management approach uses a rigorous two-tier review process. This process, an important hallmark of the CDMRP, balances scientific merit across many disciplines with the potential for fulfilling programmatic goals when making funding recommendations. The CDMRP [website](#) contains additional details regarding CDMRP's funding history and the two-tier review process.



CDMRP Management Process

## FY24 AND FY25 RESEARCH PROGRAMS

The CDMRP experienced a significant change in the number of programs appropriated in FY25. In FY24, Congress appropriated funds for 35 distinct CDMRP programs. The Full-Year Continuing Appropriations and Extensions Act, 2025, represented a significant shift with Congress appropriating \$650 million to a smaller number of individual programs and expanding the breadth of topic areas for the Peer Reviewed Cancer Research Program and the Peer Reviewed Medical Research Program. Throughout these changes, the CDMRP maintained focus on funding projects with the greatest potential impact for patients.

For more information, see the CDMRP [Research Programs](#) websites.

### FY24 and FY25 Appropriations by Program

Research Program	FY24 \$M	FY25 \$M	Research Program	FY24 \$M	FY25 \$M
Alcohol and Substance Use Disorders	\$4.0	-	Multiple Sclerosis	\$20.0	-
Alzheimer's	\$15.0	\$15.0	Neurofibromatosis	\$25.0	-
Amyotrophic Lateral Sclerosis	\$40.0	\$40.0	Ovarian Cancer	\$45.0	\$15.0
Arthritis	\$10.0	-	Pancreatic Cancer	\$15.0	-
Autism	\$15.0	-	Parkinson's	\$16.0	-
Bone Marrow Failure	\$7.5	-	Peer Reviewed Cancer	\$130.0	\$130.0
Breast Cancer	\$150.0	\$130.0	Peer Reviewed Medical	\$370.0	\$150.0
Combat Readiness-Medical	\$5.0	-	Peer Reviewed Orthopaedic	\$30.0	-
Duchenne Muscular Dystrophy	\$10.0	\$12.5	Prostate Cancer	\$110.0	\$75.0
Epilepsy	\$12.0	-	Rare Cancers	\$17.5	\$17.5
Glioblastoma	\$10.0	-	Reconstructive Transplant	\$12.0	-
Hearing Restoration	\$5.0	-	Spinal Cord Injury	\$40.0	-
Joint Warfighter Medical	\$20.0	-	Tick-Borne Disease	\$7.0	-
Kidney Cancer	\$50.0	-	Toxic Exposures	\$30.0	\$15.0
Lung Cancer	\$25.0	-	Traumatic Brain Injury and Psychological Health	\$175.0	-
Lupus	\$10.0	-	Tuberous Sclerosis Complex	\$8.0	-
Melanoma	\$40.0	\$40.0	Vision	\$20.0	-
Military Burn	\$10.0	\$10.0			
			<b>TOTALS</b>	<b>FY24 \$1,509M</b>	<b>FY25 \$650M</b>



## PARTNERSHIPS

The CDMRP represents a unique partnership among the public, Congress, researchers and the military. More than 30 years later, the community remains a cornerstone of the CDMRP. Community members, or consumers, include patients, survivors, family members, caregivers or those in partnership with a community-based organization or advisory board. Consumers actively participate throughout each program cycle and often contribute as integrated members of funded research teams, forming a unique partnership with scientists, clinicians and leading experts.

### Consumer Involvement by the Numbers



# 95

Programmatic  
Panel Members  
and Reviewers



# 640

Peer  
Reviewers



# 32

Award Mechanisms with  
Consumer Involvement

The CDMRP communicates and actively coordinates with other federal and non-federal biomedical research funding organizations to identify gaps, synergize investments and prevent duplication of effort. Examples of interagency collaborations include, but are not limited to, the following:

### Interagency Committees\*

The CDMRP participates in several interagency committees coordinating federal efforts to address health care and research related to **autism; disabilities, independent living and rehabilitation; kidney disease; muscular dystrophy; women's health**, with a special focus on active-duty and Veteran women; and other topics.

### International Consortia

The **International Rare Diseases Consortium** unites multi-national community partners committed to rare diseases research, including the CDMRP.

### Local Boards

The CDMRP serves on **local advisory boards** to accelerate innovation, development and delivery of biotechnology to grow biohealth capacity.

### Networks & Initiatives

The CDMRP is a member of the **Complement Animal Research In Experimentation (Complement-ARIE) Program**, a collaborative workgroup of public and private sectors focused on accelerating the adoption of alternative research models to accurately predict human health outcomes.

\* Women's Health Research Initiative/DOW-VA Women's Health Collaborative, Kidney Interagency Coordinating Committee, Interagency Committee on Disability Research, Interagency Autism Coordinating Committee and Muscular Dystrophy Coordinating Committee


# MANAGING, MONITORING AND EVALUATING RESEARCH INVESTMENTS

The CDMRP drives mission success by carefully managing research investments, which facilitates successful completion of the proposed study and provides accountability of results to stakeholders.

During this report period, the CDMRP fully executed FY24 appropriations, announced funding opportunities for FY25 programs and actively managed a portfolio of awards from previous fiscal years still in their period of performance. This year's efforts include:

	<p><i>Ongoing Research</i> Continued management of <b>4,237</b> active research awards</p>	<p><i>FY24 Awards</i> Invested <b>\$955.13M</b> in <b>794</b> new projects</p>	<p><i>FY25 Appropriations</i> Initiated management of <b>\$650M</b> in appropriations across <b>12</b> programs</p>
--	--	--	---

Investments in groundbreaking research span the full spectrum of medical research and development, including basic, applied, translational and clinical research, enabling CDMRP to fill critical gaps for maximum impact. The graphic below shows the percentage of the CDMRP's FY24 investments based on awardee-identified research stage from bench to bedside.



Newly funded FY24 research projects join an active portfolio of research awards that the CDMRP manages throughout their periods of performance, monitoring progress and direct outputs that communicate research results through peer-reviewed publications, presentations and patents. Between October 2024 and September 2025, CDMRP-funded research produced 1,917 outputs, providing the first step towards patient impact.

<p><b>504</b> <b>Publications</b></p>		<p><b>1,327</b> <b>Presentations</b></p>	
<p><b>86</b> <b>Patents</b></p>			

## IMPACT HIGHLIGHTS

Research outputs advance scientific progress, leading to further discovery and development of diagnostics, interventions and changes in clinical practice. The CDMRP continues to monitor and evaluate the contribution of CDMRP-funded research results as they translate into long-term outcomes impacting patients and the health care system. Investments in basic science often take a decade or longer to generate long-term outcomes. In FY24 and FY25, the CDMRP identified more than 50 outcomes resulting in part from the contributions of CDMRP funding, with selected outcomes highlighted below and on the next page.

### CLINICAL TRIALS



Development of a **small molecule**, VRG50635, and **oligonucleotide-based therapeutic**, AS-202, for the treatment of **amyotrophic lateral sclerosis**. Ongoing efforts include conducting phase 1b clinical trials for VRG50653 and defining the development, regulatory and commercialization pathways for AS-202.



Completion of a phase 1 clinical trial testing the **personalized neoantigen cancer vaccine**, NeoVax, for **renal cell carcinoma**. None of the trial participants experienced disease recurrence. Another phase 1 clinical trial will evaluate the combination of NeoVax with ipilimumab for the treatment of high-risk disease.



Feasibility testing and ruggedization of Teledyne's PeakSleep™, a **wearable device** for the treatment of **insomnia** in Service Members. Follow-on funding supports a phase 2 clinical trial for PeakSleep™ at the Walter Reed Army Institute for Research, with expected trial completion in 2026.

### DEVICES



Development of a **communication device** to provide tactile sensation from a **prosthetic hand** to the brain and improve patient quality of life. Amputees at the Walter Reed Army National Military Medical Center began receiving this prosthetic hand system implantation in 2024.



Optimization and patenting of the **falloscope**, a fallopian tube-specific imaging device, to create a simplified and highly effective system for early detection of **ovarian cancer**.



Optimization of **flash phototherapy** to assist with **sleep disorders**, jet lag or night shift transition, leading to the development of the commercially available Lumos Smart Sleep Mask.



## TRANSLATED TO CLINICAL USE



FDA approval of mirdametrinib as a **treatment** option for adult and pediatric patients living with **neurofibromatosis type 1** and **symptomatic plexiform neurofibromas**.



FDA approval of darolutamide in combination with androgen deprivation therapy as a **treatment** option for patients with metastatic castration-sensitive **prostate cancer**.



FDA premarket approval of Lungpacer AeroPace® System, a minimally invasive **respiratory health therapy** to train and strengthen the diaphragm to assist with weaning patients from mechanical ventilation.



Expanded public access of Project ECHO Autism Transition/Adult Health Care Program, an **online program for health care providers** demonstrated effective for increasing access to care for youths with **autism spectrum disorder** transitioning to adulthood that face transportation, distance, or other barriers. Project ECHO currently includes more than 6,000 active members and 10 flagship programs that conduct over 160 training sessions yearly.



Validation of a **multi-protein, serum-based assay**, Octave® Multiple Sclerosis Disease Activity Test, that measures disease activity for **multiple sclerosis** patients. The test, now available nationwide in more than 35 clinics, helps patients and providers with disease management over time.



Development of Strength Training Rehabilitation Incorporating Power Exercises, a **rehabilitation strategy** incorporating power-based exercises into standard of care, to improve return to duty for Service Members with **patellofemoral pain**, or pain in front of and around the kneecap.



Validation and public release of the Nerve and Tendon Transfer Surgery Decision Aid, an **online tool** to support individuals with cervical **spinal cord injury** and their health care providers with making informed choices regarding upper-extremity surgery, specifically comparing tendon transfer, nerve transfer and no surgery options.



Development, dissemination and local implementation of a **return to duty protocol** for law enforcement officers after suffering a **traumatic brain injury**.



## FY24 PROGRAMS AND INVESTMENTS

The CDMRP takes pride in our organization’s transparency and accountability. The following table summarizes FY24 programs and their priorities and appropriations, applications received and funded, and research investments less withholds and management costs. The CDMRP remains dedicated to minimizing management costs to maximize the funds available to support research. Management costs averaged 6.17 percent of total CDMRP FY24 appropriations.

Applications Funded/Received	Withholds and Management Costs	Research Investment																											
<b>\$4.0M</b>	<b>Alcohol and Substance Use Disorders</b>	Support translational research to increase and improve medication options for alcohol, opioid and other substance use disorders, particularly when they co-occur with other mental health conditions.																											
	1/5	<table border="1"> <tr> <td>DHA R&amp;D-MRDC .....</td> <td>\$86,932</td> <td rowspan="3">Consortium Award With Community-Based Participatory Research .....</td> <td rowspan="3">\$3,525,000</td> </tr> <tr> <td>SBIR/STTR* .....</td> <td>\$133,000</td> </tr> <tr> <td>Mgt Costs .....</td> <td>\$255,068</td> </tr> <tr> <td colspan="2"><b>Total: \$475,000</b></td> <td colspan="2"><b>Total: \$3,525,000</b></td> </tr> </table>	DHA R&D-MRDC .....	\$86,932	Consortium Award With Community-Based Participatory Research .....	\$3,525,000	SBIR/STTR* .....	\$133,000	Mgt Costs .....	\$255,068	<b>Total: \$475,000</b>		<b>Total: \$3,525,000</b>																
DHA R&D-MRDC .....	\$86,932	Consortium Award With Community-Based Participatory Research .....	\$3,525,000																										
SBIR/STTR* .....	\$133,000																												
Mgt Costs .....	\$255,068																												
<b>Total: \$475,000</b>		<b>Total: \$3,525,000</b>																											
<b>\$15.0M</b>	<b>Alzheimer’s</b>	Support transformative, solutions-oriented research to address critical needs and improve quality of life for people living with Alzheimer’s disease and related dementias.																											
	14/167	<table border="1"> <tr> <td>DHA R&amp;D-MRDC .....</td> <td>\$325,988</td> <td rowspan="4">Transforming Care Award .....</td> <td rowspan="4">\$1,399,917</td> </tr> <tr> <td>SBIR/STTR.....</td> <td>\$501,000</td> <td>Transforming Diagnosis Award .....</td> <td>\$3,790,657</td> </tr> <tr> <td>Mgt Costs .....</td> <td>\$915,202</td> <td>Transforming Research Award .....</td> <td>\$7,962,913</td> </tr> <tr> <td></td> <td></td> <td>Modification to ongoing awards .....</td> <td>\$104,323</td> </tr> <tr> <td colspan="2"><b>Total: \$1,742,190</b></td> <td colspan="2"><b>Total: \$13,257,810</b></td> </tr> </table>	DHA R&D-MRDC .....	\$325,988	Transforming Care Award .....	\$1,399,917	SBIR/STTR.....	\$501,000	Transforming Diagnosis Award .....	\$3,790,657	Mgt Costs .....	\$915,202	Transforming Research Award .....	\$7,962,913			Modification to ongoing awards .....	\$104,323	<b>Total: \$1,742,190</b>		<b>Total: \$13,257,810</b>								
DHA R&D-MRDC .....	\$325,988	Transforming Care Award .....	\$1,399,917																										
SBIR/STTR.....	\$501,000			Transforming Diagnosis Award .....			\$3,790,657																						
Mgt Costs .....	\$915,202			Transforming Research Award .....			\$7,962,913																						
				Modification to ongoing awards .....	\$104,323																								
<b>Total: \$1,742,190</b>		<b>Total: \$13,257,810</b>																											
<b>\$40.0M</b>	<b>Amyotrophic Lateral Sclerosis</b>	Support impactful research to expedite the pathway from bench science to clinical trials for new therapeutic approaches and treatments for amyotrophic lateral sclerosis.																											
	27/156	<table border="1"> <tr> <td>DHA R&amp;D-MRDC .....</td> <td>\$869,898</td> <td rowspan="5">Clinical Outcomes and Biomarkers Award ..</td> <td rowspan="5">\$5,411,117</td> </tr> <tr> <td>SBIR/STTR.....</td> <td>\$1,335,000</td> <td>Pilot Clinical Trial Award -</td> <td></td> </tr> <tr> <td>Mgt Costs .....</td> <td>\$2,244,109</td> <td>Biomarker-Driven Interventions.....</td> <td>\$2,180,261</td> </tr> <tr> <td></td> <td></td> <td>Pilot Clinical Trial Award - Clinical Care Tier.</td> <td>\$5,217,670</td> </tr> <tr> <td></td> <td></td> <td>Therapeutic Development Award.....</td> <td>\$9,001,179</td> </tr> <tr> <td></td> <td></td> <td>Therapeutic Idea Award .....</td> <td>\$13,740,766</td> </tr> <tr> <td colspan="2"><b>Total: \$4,449,007</b></td> <td colspan="2"><b>Total: \$35,550,993</b></td> </tr> </table>	DHA R&D-MRDC .....	\$869,898	Clinical Outcomes and Biomarkers Award ..	\$5,411,117	SBIR/STTR.....	\$1,335,000	Pilot Clinical Trial Award -		Mgt Costs .....	\$2,244,109	Biomarker-Driven Interventions.....	\$2,180,261			Pilot Clinical Trial Award - Clinical Care Tier.	\$5,217,670			Therapeutic Development Award.....	\$9,001,179			Therapeutic Idea Award .....	\$13,740,766	<b>Total: \$4,449,007</b>		<b>Total: \$35,550,993</b>
DHA R&D-MRDC .....	\$869,898	Clinical Outcomes and Biomarkers Award ..	\$5,411,117																										
SBIR/STTR.....	\$1,335,000			Pilot Clinical Trial Award -																									
Mgt Costs .....	\$2,244,109			Biomarker-Driven Interventions.....			\$2,180,261																						
				Pilot Clinical Trial Award - Clinical Care Tier.			\$5,217,670																						
				Therapeutic Development Award.....	\$9,001,179																								
		Therapeutic Idea Award .....	\$13,740,766																										
<b>Total: \$4,449,007</b>		<b>Total: \$35,550,993</b>																											
<b>\$10.0M</b>	<b>Arthritis</b>	Support high impact research to optimize the health and well-being of all people affected by arthritis and improve Service Member readiness.																											
	12/118	<table border="1"> <tr> <td>DHA R&amp;D-MRDC .....</td> <td>\$216,652</td> <td rowspan="2">Clinical Research Award .....</td> <td rowspan="2">\$2,996,880</td> </tr> <tr> <td>SBIR/STTR.....</td> <td>\$365,000</td> <td>Focused Research Award.....</td> <td>\$5,701,158</td> </tr> <tr> <td>Mgt Costs .....</td> <td>\$720,310</td> <td></td> <td></td> </tr> <tr> <td colspan="2"><b>Total: \$1,301,962</b></td> <td colspan="2"><b>Total: \$8,698,038</b></td> </tr> </table>	DHA R&D-MRDC .....	\$216,652	Clinical Research Award .....	\$2,996,880	SBIR/STTR.....	\$365,000	Focused Research Award.....	\$5,701,158	Mgt Costs .....	\$720,310			<b>Total: \$1,301,962</b>		<b>Total: \$8,698,038</b>												
DHA R&D-MRDC .....	\$216,652	Clinical Research Award .....	\$2,996,880																										
SBIR/STTR.....	\$365,000			Focused Research Award.....	\$5,701,158																								
Mgt Costs .....	\$720,310																												
<b>Total: \$1,301,962</b>		<b>Total: \$8,698,038</b>																											

\* Small Business Innovation Research/Small Business Technology Transfer

Applications Funded/Received	Withholds and Management Costs	Research Investment
<b>\$15.0M</b>	<b>Autism</b>	Promote innovative research that advances the understanding of autism spectrum disorder and leads to improved outcomes.
17/117	DHA R&D-MRDC ..... \$326,000 SBIR/STTR..... \$501,000 Mgt Costs ..... \$833,294 <b>Total: \$1,660,294</b>	Career Development Award..... \$2,288,833 Clinical Trial Award ..... \$6,252,990 Discovery Award..... \$1,499,981 Idea Development Award ..... \$3,297,902 <b>Total: \$13,339,706</b>
<b>\$7.5M</b>	<b>Bone Marrow Failure</b>	Support innovative research approaches based on sound scientific evidence that will advance the understanding, prevention and treatment of inherited and acquired bone marrow failure diseases.
9/44	DHA R&D-MRDC ..... \$162,751 SBIR/STTR..... \$250,000 Mgt Costs ..... \$503,681 <b>Total: \$916,432</b>	Idea Development Award ..... \$4,698,545 Investigator-Initiated Research Award ..... \$1,885,023 <b>Total: \$6,583,568</b>
<b>\$150.0M</b>	<b>Breast Cancer</b>	End breast cancer by funding innovative, high-impact research through a partnership of scientists and consumers.
66/1150	DHA R&D-MRDC ..... \$3,261,883 SBIR/STTR..... \$5,003,000 Mgt Costs ..... \$10,195,802 <b>Total: \$18,460,684</b>	Breakthrough Award Levels 1 and 2 ..... \$43,629,079 Breakthrough Award Level 3 ..... \$31,016,412 Breakthrough Award Level 4 ..... \$21,177,779 Clinical Research Extension Award ..... \$15,612,638 Era of Hope Scholar Award..... \$5,540,949 Expansion Award ..... \$8,374,762 Transformative Breast Cancer Consortium Development Award ..... \$161,000 Modification to ongoing awards ..... \$6,026,697 <b>Total: \$131,539,316</b>
<b>\$432.2K</b>	<b>Breast Cancer Semipostal</b>	Breakthrough Award Levels 1 and 2 ..... \$432,208 <b>Total: \$432,208</b>
<b>\$5.0M</b>	<b>Combat Readiness—Medical</b>	Support development of innovative, high-impact solutions to increase medical readiness, diagnose and treat life threatening injuries, reduce morbidity and mortality and promote positive long-term outcomes for the Warfighter.
3/55	DHA R&D-MRDC ..... \$109,000 SBIR/STTR..... \$165,000 Mgt Costs ..... \$392,954 <b>Total: \$666,954</b>	Military Medical Research and Development Award ..... \$132,000 Rapid Development and Translation Research Award ..... \$1,647,774 Translational Research Award ..... \$2,553,272 <b>Total: \$4,333,046</b>
<b>\$10.0M</b>	<b>Duchenne Muscular Dystrophy</b>	Support discovery, development and delivery of therapeutics for Duchenne muscular dystrophy at all stages of the disease.
10/60	DHA R&D-MRDC ..... \$217,000 SBIR/STTR..... \$334,000 Mgt Costs ..... \$689,364 <b>Total: \$1,240,364</b>	Clinical/Translational Research Award - Funding Level 1 ..... \$1,840,945 Clinical/Translational Research Award - Funding Level 2 ..... \$5,850,696 Idea Development Award ..... \$1,067,995 <b>Total: \$8,759,636</b>

Applications Funded/ Received	Withholds and Management Costs	Research Investment
<b>\$12.0M</b>	<b>Epilepsy</b>	Support longitudinal epidemiological research to better understand the development of epilepsy following a traumatic brain injury and to improve patient care and outcomes.
16/84	DHA R&D-MRDC ..... \$261,000 SBIR/STTR..... \$400,000 Mgt Costs ..... \$346,321	Idea Development Award ..... \$3,994,427 Leveraging Research Award ..... \$777,537 Research Partnership Award ..... \$4,739,603 Virtual Post-Traumatic Epilepsy Research Center ..... \$1,475,138 Modification to ongoing awards ..... \$5,794
	<b>Total: \$1,007,321</b>	<b>Total: \$10,992,499</b>
<b>\$10.0M</b>	<b>Glioblastoma</b>	Support rigorous, high-impact research to drive scientific discovery and advances in diagnosis, treatment and quality of life for patients with glioblastoma.
18/440	DHA R&D-MRDC ..... \$216,968 SBIR/STTR..... \$365,000 Mgt Costs ..... \$756,529	Hypothesis Development Award..... \$3,007,157 Resource Development Award ..... \$1,565,775 Transformative Consortium Award..... \$4,088,571
	<b>Total: \$1,338,497</b>	<b>Total: \$8,661,503</b>
<b>\$5.0M</b>	<b>Hearing Restoration</b>	Develop regenerative strategies and improved diagnostic approaches to reduce the burden of acquired hearing loss on Service Members.
8/46	DHA R&D-MRDC ..... \$109,000 SBIR/STTR..... \$166,000 Mgt Costs ..... \$264,523	Focused Research Award - Funding Level 1.. \$2,130,627 Focused Research Award - Funding Level 2.. \$2,318,334 Modification to ongoing awards ..... \$11,516
	<b>Total: \$539,523</b>	<b>Total: \$4,460,477</b>
<b>\$20.0M</b>	<b>Joint Warfighter Medical</b>	Support the logical continuation of DOD-funded research that augments and accelerates the development of high-priority military medical solutions.
8*/44	DHA R&D-MRDC ..... \$434,840 SBIR/STTR..... \$666,000 Mgt Costs ..... \$268,964	Joint Warfighter Medical Research Program Advanced Development ..... \$8,985,000 Military Medical Research and Development Award ..... \$7,558,193 Modification to ongoing awards ..... \$2,087,003
	<b>Total: \$1,369,804</b>	<b>Total: \$18,630,196</b>
<b>\$50.0M</b>	<b>Kidney Cancer</b>	Promote innovative, high impact research to understand, diagnosis, treat and improve quality of life for all forms of kidney cancer.
47/280	DHA R&D-MRDC ..... \$1,087,000 SBIR/STTR..... \$1,669,000 Mgt Costs ..... \$2,598,612	Academy of Kidney Cancer Investigators - Early-Career Scholar Award ..... \$2,083,413 Academy of Kidney Cancer Investigators - Leadership Award..... \$2,297,631 Concept Award..... \$1,434,925 Idea Development Award ..... \$8,101,186 Idea Development Award - Partnering PI Option ..... \$17,658,614 Postdoctoral and Clinical Fellowship Award ..... \$1,640,279 Translational Research Partnership Award.. \$2,539,997 Modification to ongoing awards ..... \$8,889,343
	<b>Total: \$5,354,612</b>	<b>Total: \$44,645,388</b>

\*Joint Warfighter Medical Execution Management Breakdown: three awards funded with 6.3 dollars, five awards funded with 6.4 dollars and four mods managed by the CDMRP.

Applications Funded/Received	Withholds and Management Costs	Research Investment
<b>\$25.0M</b>	<b>Lung Cancer</b>	Support and integrate research from multiple disciplines for risk assessment, prevention, early detection, diagnosis, management and treatment for the control and cure of lung cancer.
35/367	DHA R&D-MRDC ..... \$543,769 SBIR/STTR..... \$834,000 Mgt Costs ..... \$1,224,294 <b>Total: \$2,602,063</b>	Career Development Award..... \$1,821,911 Concept Award..... \$1,918,037 Idea Development Award..... \$12,851,159 Patient-Centered Outcomes and Survivorship Award..... \$1,795,237 Translational Research Award - Funding Level 1 ..... \$2,359,563 Translational Research Award - Funding Level 2 ..... \$1,652,030 <b>Total: \$22,397,937</b>
<b>\$10.0M</b>	<b>Lupus</b>	Fund research to understand, prevent and diagnose lupus and to improve treatments and quality of life of patients.
15/56	DHA R&D-MRDC ..... \$216,370 SBIR/STTR..... \$334,000 Mgt Costs ..... \$755,231 <b>Total: \$1,305,601</b>	Idea Award..... \$2,695,576 Impact Award..... \$5,998,823 <b>Total: \$8,694,399</b>
<b>\$40.0M</b>	<b>Melanoma</b>	Fund research that addresses unmet needs in melanoma prevention and interception, rare melanomas, and survivorship.
37/318	DHA R&D-MRDC ..... \$870,000 SBIR/STTR..... \$1,335,000 Mgt Costs ..... \$2,389,511 <b>Total: \$4,594,511</b>	Focused Program Award - Rare Melanomas ..... \$5,575,718 Idea Award..... \$6,175,993 Melanoma Academy Scholar Award ..... \$2,335,600 Survivorship Research Award..... \$2,430,203 Team Science Award ..... \$18,887,975 <b>Total: \$35,405,489</b>
<b>\$10.0M</b>	<b>Military Burn</b>	Fund burn-focused research that innovates, refines and/or tests novel burn therapies, technologies and/or clinical guidelines that facilitate delivery of high-quality burn care in resource-limited, distributed military operational environments.
4/64	DHA R&D-MRDC ..... \$217,937 SBIR/STTR..... \$333,000 Mgt Costs ..... \$502,801 <b>Total: \$1,053,737</b>	Clinical Translational Research Award ..... \$22,367 Patient-Centered Research Award ..... \$2,134,000 Technology/Therapeutic Development Award ..... \$6,788,158 Modification to ongoing awards ..... \$11,738 <b>Total: \$8,956,263</b>

Applications Funded/Received	Withholds and Management Costs	Research Investment
<b>\$20.0M</b>	<b>Multiple Sclerosis</b>	Support research to prevent, cure, reverse or slow the progression of multiple sclerosis.
30/149	DHA R&D-MRDC ..... \$434,829 SBIR/STTR..... \$667,000 Mgt Costs ..... \$1,060,689 <b>Total: \$2,162,518</b>	Clinical Trial Award ..... \$1,736,759 Early Investigator Research Award..... \$2,863,317 Exploration - Hypothesis Development Award ..... \$2,248,223 Investigator-Initiated Research Award ..... \$10,989,183 <b>Total: \$17,837,482</b>
<b>\$25.0M</b>	<b>Neurofibromatosis</b>	Promote research directed toward the understanding, diagnosis and treatment of NF1, NF2 and schwannomatosis to enhance the quality of life for persons with these disorders.
24/129	DHA R&D-MRDC ..... \$544,000 SBIR/STTR..... \$834,000 Mgt Costs ..... \$923,648 <b>Total: \$2,301,648</b>	Early Investigator Research Award.....\$651,997 Exploration - Hypothesis Development Award .....\$951,049 Investigator-Initiated Research Award ..... \$5,977,356 New Investigator Award - Early Stage Investigator ..... \$1,881,478 Synergistic Idea Award ..... \$6,795,664 Modification to ongoing awards ..... \$6,440,808 <b>Total: \$22,698,352</b>
<b>\$45.0M</b>	<b>Ovarian Cancer</b>	Support patient-centered research to prevent, detect, treat and cure ovarian cancer to enhance the health and well-being of all women impacted by this disease.
42/306	DHA R&D-MRDC ..... \$979,000 SBIR/STTR..... \$1,501,000 Mgt Costs ..... \$3,121,668 <b>Total: \$5,601,668</b>	Investigator-Initiated Research Award ..... \$23,222,953 Ovarian Cancer Academy - Early-Career Investigator Award ..... \$3,365,510 Ovarian Cancer Academy - Leadership Award..... \$2,795,138 Ovarian Cancer Clinical Trial Academy - Early-Career Investigator Award ..... \$3,223,807 Pilot Award..... \$3,828,532 Teal Expansion Award ..... \$2,962,392 <b>Total: \$39,398,332</b>
<b>\$15.0M</b>	<b>Pancreatic Cancer</b>	Support rigorous, innovative, high-impact pancreatic cancer research that leads to prevention, earlier diagnosis, new therapeutic tools and improved outcomes.
24/119	DHA R&D-MRDC ..... \$325,072 SBIR/STTR..... \$501,000 Mgt Costs ..... \$594,653 <b>Total: \$1,420,725</b>	Focused Pilot Award ..... \$1,214,712 Idea Development Award..... \$8,893,079 Translational Research Partnership Award.. \$3,471,484 <b>Total: \$13,579,275</b>

Applications Funded/Received	Withholds and Management Costs	Research Investment
<b>\$16.0M</b>	<b>Parkinson's</b>	Improve the health and lives of people with Parkinson's disease through innovative, clinically meaningful treatments.
14/171	DHA R&D-MRDC ..... \$348,000 SBIR/STTR..... \$531,000 Mgt Costs ..... \$875,781 <b>Total: \$1,754,781</b>	Early Investigator Research Award.....\$399,966 Investigator-Initiated Research Award ..... \$13,845,253 <b>Total: \$14,245,219</b>
<b>\$130.0M</b>	<b>Peer Reviewed Cancer*</b>	Improve mission readiness and quality of life by decreasing the burden of cancer on Service Members, their Families, Veterans and the American public.
65/448	DHA R&D-MRDC .....\$2,827,000 SBIR/STTR.....\$4,336,000 Mgt Costs .....\$8,141,229 <b>Total: \$15,304,229</b>	Advancing Cancer Care Through Clinical Trials Award..... \$24,455,238 Career Development Award - Scholar Option ..... \$9,326,489 Convergent Science Cancer Consortium Award..... \$31,310,831 Idea Award..... \$18,543,778 Impact Award..... \$20,384,340 Patient Well-Being and Survivorship Award..... \$7,544,607 Virtual Cancer Center Director Award..... \$2,788,865 Modification to ongoing awards .....\$341,623 <b>Total: \$114,695,771</b>
<b>\$370.0M</b>	<b>Peer Reviewed Medical**</b>	Encourage, identify, select and manage medical research projects of clear scientific merit that lead to impactful advances in health care of Service Members, Veterans and their Families.
136/942	DHA R&D-MRDC .....\$8,047,000 SBIR/STTR.....\$12,340,000 Mgt Costs .....\$21,143,347 <b>Total: \$41,530,347</b>	Clinical Trial Award ..... \$64,889,668 Discovery Award..... \$15,837,298 Impact Award..... \$62,822,752 Investigator-Initiated Research Award ..... \$40,955,879 Lifestyle and Behavioral Health Interventions Research Award..... \$8,273,509 Technology/Therapeutic Development Award ..... \$84,521,829 Modification to ongoing awards ..... \$51,168,718 <b>Total: \$328,469,653</b>
<b>\$30.0M</b>	<b>Peer Reviewed Orthopaedic</b>	Support high-impact and clinically relevant research to advance treatment and rehabilitation from orthopaedic injuries sustained during combat and service-related activities to maximize return to duty.
15/146	DHA R&D-MRDC ..... \$652,000 SBIR/STTR.....\$1,001,000 Mgt Costs .....\$2,064,668 <b>Total: \$3,717,668</b>	Applied Research Award..... \$2,998,029 Clinical Translational Research Award ..... \$4,419,790 Clinical Trial Award - Funding Level 1 ..... \$12,270,785 Women's Health Research Award..... \$4,402,085 Modification to ongoing awards ..... \$2,191,643 <b>Total: \$26,282,332</b>

\*Investments by topic area available in Appendix Table A-1

\*\*Investments by topic area available in Appendix Table A-2

Applications Funded/Received	Withholds and Management Costs	Research Investment		
<b>\$110.0M</b>	<b>Prostate Cancer</b>	Fund research that will eliminate death and suffering from prostate cancer.		
78/545	DHA R&D-MRDC .....	\$2,391,296	Data Science Award .....	\$9,942,805
	SBIR/STTR.....	\$3,671,000	Early Investigator Research Award.....	\$5,617,568
	Mgt Costs .....	\$6,530,912	Exploration - Hypothesis Development Award .....	\$3,117,825
			Health Equity Research and Outcomes Improvement Consortium Award .....	\$296,513
			Idea Development Award.....	\$55,402,372
		Implementation Science Award .....	\$5,840,525	
		Physician Research Award .....	\$9,369,168	
		Modification to ongoing awards .....	\$7,820,016	
	<b>Total: \$12,593,208</b>	<b>Total: \$97,406,792</b>		
<b>\$17.5M</b>	<b>Rare Cancers</b>	Support research to greatly improve outcomes for people with rare cancers through discovery, community building and expansion of knowledge across the cancer landscape.		
31/342	DHA R&D-MRDC .....	\$380,880	Concept Award.....	\$2,072,323
	SBIR/STTR.....	\$584,000	Idea Development Award .....	\$6,508,944
	Mgt Costs .....	\$1,102,809	Resource Community Development Award .	\$6,851,044
	<b>Total: \$2,067,689</b>	<b>Total: \$15,432,311</b>		
<b>\$12.0M</b>	<b>Reconstructive Transplant</b>	Support research to advance the science and standardized clinical practice of vascularized composite allotransplantation to improve access, safety and quality of life for catastrophically injured individuals.		
16/62	DHA R&D-MRDC .....	\$261,000	Advanced Technology Development Award .	\$3,793,535
	SBIR/STTR.....	\$400,000	Idea Discovery Award .....	\$1,072,304
	Mgt Costs .....	\$665,646	Investigator-Initiated Research Award .....	\$5,031,520
			Qualitative Research Validation and Implementation Award .....	\$500,000
		Modification to ongoing awards .....	\$275,995	
	<b>Total: \$1,326,646</b>	<b>Total: \$10,673,354</b>		
<b>\$40.0M</b>	<b>Spinal Cord Injury</b>	Advance the development, translation and ultimate adoption of health care solutions for people living with spinal cord injury, their families and/or care partners.		
27/153	DHA R&D-MRDC .....	\$869,876	Clinical Translation Research Award .....	\$8,607,547
	SBIR/STTR.....	\$1,335,000	Clinical Trial Award .....	\$14,085,118
	Mgt Costs .....	\$1,813,752	Investigator-Initiated Research Award .....	\$5,486,624
			Translational Research Award .....	\$6,934,122
			Modification to ongoing awards .....	\$867,961
	<b>Total: \$4,018,628</b>	<b>Total: \$35,981,372</b>		

Applications Funded/Received	Withholds and Management Costs	Research Investment
------------------------------	--------------------------------	---------------------

**\$7.0M** **Tick-Borne Disease** Support research that contributes to the development of solutions to prevent, detect and resolve Lyme disease and other tick-borne diseases and conditions.

7/43	DHA R&D-MRDC .....	\$151,968	Idea Development Award .....	\$2,502,376
	SBIR/STTR .....	\$234,000	Therapeutic/Diagnostic Research Award .....	\$3,868,069
	Mgt Costs .....	\$243,587		
	<b>Total: \$629,555</b>		<b>Total: \$6,370,445</b>	

**\$30.0M** **Toxic Exposures** Support research to prevent, minimize and mitigate the impact of military-related toxic exposures and improve the health and quality of life of those affected.

24/225	DHA R&D-MRDC .....	\$652,000	Clinical Trial Award .....	\$9,399,656
	SBIR/STTR .....	\$1,001,000	Investigator-Initiated Research Award .....	\$7,404,232
	Mgt Costs .....	\$2,246,365	Translational Research Award .....	\$9,296,747
	<b>Total: \$3,899,365</b>		<b>Total: \$26,100,635</b>	

**\$175.0M** **Traumatic Brain Injury and Psychological Health** Support research to optimize the prevention, assessment and treatment of psychological health conditions and/or traumatic brain injuries.

63/222	DHA R&D-MRDC .....	\$3,805,553	Clinical Trial Award .....	\$52,744,218
	SBIR/STTR .....	\$5,837,000	Emerging Topics Research Award .....	\$34,876,548
	Mgt Costs .....	\$10,098,554	Focused Program Award .....	\$31,551,088
			Health Services Research Award .....	\$20,467,731
			Translational Research Award .....	\$11,851,472
			Modification to ongoing awards .....	\$3,767,837
	<b>Total: \$19,741,107</b>		<b>Total: \$155,258,894</b>	

**\$8.0M** **Tuberous Sclerosis Complex** Support research to promote mechanistic understanding of and clinical applications to tuberous sclerosis complex.

11/46	DHA R&D-MRDC .....	\$173,413	Clinical Translational Research Award .....	\$1,683,194
	SBIR/STTR .....	\$267,000	Exploration - Hypothesis Development Award .....	\$982,541
	Mgt Costs .....	\$416,783	Idea Development Award .....	\$4,477,069
	<b>Total: \$857,196</b>		<b>Total: \$7,142,804</b>	

**\$20.0M** **Vision** Advance the understanding, prevention, diagnosis, mitigation and treatment of service-connected eye injury or visual dysfunction.

19/100	DHA R&D-MRDC .....	\$433,959	Clinical Trial Award .....	\$2,218,476
	SBIR/STTR .....	\$667,000	Focused Translational Team Science Award .....	\$6,184,918
	Mgt Costs .....	\$1,100,340	Investigator-Initiated Research Award .....	\$7,638,773
			Mentored Clinical Research Award .....	\$135,765
			Translational Research Award .....	\$1,593,795
			Modification to ongoing awards .....	\$26,974
	<b>Total: \$2,201,299</b>		<b>Total: \$17,798,701</b>	

## APPENDIX A: FY24 PRCRP AND PRMRP TOPIC AREA INVESTMENT SUMMARY

Table A-1. PRCRP Investment by Topic Area

Bladder Cancer .....	\$8,918,110	Mesothelioma .....	\$990,623
Blood Cancer .....	\$36,306,336	Metastatic Cancers .....	\$-
Brain Cancer, excluding glioblastoma.....	\$3,034,016	Myeloma.....	\$-
Colorectal Cancer.....	\$13,586,499	Neuroblastoma .....	\$9,630,297
Endometrial Cancer.....	\$2,124,867	Pediatric Adolescent and Young Adult Cancers..	\$11,315,705
Esophageal Cancer .....	\$4,458,339	Pediatric Brain Tumors.....	\$2,600,416
Germ Cell Cancers.....	\$2,892,255	Stomach Cancer .....	\$1,157,875
Liver Cancer .....	\$3,231,617	Sarcoma .....	\$3,859,920
Lymphoma .....	\$4,159,043	Thyroid Cancer .....	\$3,640,987
		<b>Total: \$111,906,904</b>	

The Virtual Cancer Center Director Award, \$2,788,865, addresses multiple topic areas.

Table A-2. PRMRP Investment by Topic Area

Accelerated Aging Processes Associated with Military Service .....	\$8,870,791	Lymphedema .....	\$5,149,906
Celiac Disease .....	\$1,577,505	Malaria .....	\$19,682,414
Computational Biology for Precision Health .....	\$14,900,099	Maternal Mental Health .....	\$14,208,256
Congenital Cytomegalovirus .....	\$706,274	Mitochondrial Disease.....	\$3,694,330
Congenital Heart Disease .....	\$17,358,325	Musculoskeletal Disorders, related to acute and chronic bone conditions and injuries .....	\$34,577,327
Dystonia .....	\$1,675,000	Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome .....	\$389,161
Eating Disorders.....	\$-	Myotonic Dystrophy.....	\$431,750
Ehlers-Danlos Syndrome .....	\$1,934,543	Nephrotic Syndrome.....	\$5,522,036
Epidermolysis Bullosa .....	\$2,363,914	Neuroactive Steroids .....	\$3,950,890
Far-UVC Germicidal Light .....	\$-	Pancreatitis.....	\$2,837,897
Fibrous Dysplasia/McCune-Albright Syndrome .	\$3,062,579	Peripheral Neuropathy.....	\$3,027,587
Focal Segmental Glomerulosclerosis .....	\$3,640,674	Polycystic Kidney Disease.....	\$15,651,280
Food Allergies .....	\$3,309,999	Proteomics .....	\$18,857,959
Fragile X.....	\$7,742,222	Pulmonary Fibrosis.....	\$1,469,253
Frontotemporal Degeneration .....	\$300,387	Respiratory Health .....	\$16,941,926
Guillain-Barre Syndrome .....	\$-	Rett Syndrome .....	\$3,226,258
Hepatitis B .....	\$4,728,039	Scleroderma .....	\$10,883,458
Hereditary Ataxia.....	\$12,226,343	Sickle-Cell Disease .....	\$6,156,000
Hydrocephalus.....	\$1,474,039	Suicide Prevention .....	\$5,885,391
Inflammatory Bowel Disease.....	\$6,371,203	Vascular Malformations.....	\$2,909,893
Interstitial Cystitis .....	\$1,918,945	Von Hippel-Lindau Syndrome.....	\$7,687,082
		<b>Total: \$277,300,935</b>	



Models in photographs are for illustrative purposes only. Some images were cropped to emphasize subject matter. Portions of some images were blurred for security or privacy concerns.

Photos received permissions from all sources to be used within this document where applicable.

Mention of any specified commercial products and/or processes by trade name, trademark, manufacturer, or otherwise does not necessarily constitute its endorsement, recommendation, or favoring by the U.S. government.

The views and opinions of the authors may not reflect the official policy or position of the Defense Health Agency, Department of War, or the U.S. government. The appearance of Department of War visual information does not imply or constitute Department of War endorsement.

